Cystine

Cystine

SCHEMBL457219

N[C@@H](CS)C(=O)O.N[C@@H](CSSC[C@H](N)C(=O)O)C(=O)O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.73
SLC7A11 Q9UPY5 1/20 0.73
ARG1 P05089 1/20 0.42
ARG2 P78540 1/20 0.42
NOS2 P35228 3/20 0.42
NOS1 P29475 2/20 0.42
NOS3 P29474 1/20 0.42
ENPEP Q07075 5/20 0.41
GRIK1 P39086 2/20 0.40
GRIK2 Q13002 2/20 0.40
GRM1 Q13255 2/20 0.40
GRM2 Q14416 2/20 0.40
ALOX15 P16050 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GSR P00390 2/20 0.38
SLC7A5 Q01650 1/20 0.38
GRM8 O00222 1/20 0.38
GRM6 O15303 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cystine SCHEMBL457216 1.00 PTGS1 (0.73) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL457217 1.00 PTGS1 (0.73) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL27673473 0.92 PTGS1 (0.61) PTGS1SLC7A11ARG1ARG2NOS2
Cysteine SCHEMBL3416421 0.90 PTGS1 (0.64) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL15667872 0.90 PTGS1 (0.58) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL1983072 0.88 PTGS1 (0.52) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL27890268 0.88 PTGS1 (0.52) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL7442337 0.88 PTGS1 (0.52) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL5018669 0.88 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2
Cystine SCHEMBL8332360 0.88 PTGS1 (0.50) PTGS1SLC7A11ARG1ARG2NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12022829-B2 Water-dispersible fine particle TOYOBO CO., LTD. (JP) 2024-07-02 US disclosed
WO-2023083361-A1 NEW METHOD FOR IMPROVING QUALITY OF PLATELETS 上海循曜生物科技有限公司 2023-05-19 WO disclosed
WO-2023069598-A1 CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS THE TRUSTEES OF INDIANA UNIVERSITY (US) 2023-04-27 WO disclosed
US-20220030861-A1 WATER-DISPERSIBLE FINE PARTICLE TOYOBO CO., LTD. (JP) 2022-02-03 US disclosed
EP-3858136-A1 WATER-DISPERSIBILE FINE PARTICLE TOYOBO CO., LTD. (JP) 2021-08-04 EP disclosed
EP-3837281-A1 PROTEIN FRAGMENTATION CONTROL STRATEGY BY RE-OXIDATION IN DOWNSTREAM CHROMATOGRAPHY Bristol-Myers Squibb Company (US) 2021-06-23 EP disclosed
WO-2020241562-A1 NANOPARTICLES AND METHOD FOR PRODUCING SAME ユーハ味覚糖株式会社 2020-12-03 WO disclosed
CN-111529465-A Wash-free hair loss prevention and hair growth nutrient solution and preparation method thereof 南京夏悦贸易有限公司 2020-08-14 CN disclosed
WO-2020066912-A1 WATER DISPERSIBILE FINE PARTICLE 東洋紡株式会社 2020-04-02 WO disclosed
WO-2020037016-A1 PROTEIN FRAGMENTATION CONTROL STRATEGY BY RE-OXIDATION IN DOWNSTREAM CHROMATOGRAPHY BRISTOL-MYERS SQUIBB COMPANY (US) 2020-02-20 WO disclosed
US-6348451-B1 WOUND HEALING AGENTS FOR ANIMALS PRO-NEURON, INC. 2002-02-19 US disclosed
EP-1052963-A1 COMPOSITIONS AND METHODS OF TREATING KERATIN-RELATED DISORDERS AND CONDITIONS Buck, Carol J. (US) 2000-11-22 EP disclosed
US-6117364-A COMPRISING CINNAMALDEHYDE AND SPECIFIED ORGANOSULFUR COMPOUND(S); FREE OF ALKYLPHENOL ETHOXY COMPOUNDS; DOES NOT HAVE OIL FIELD ALDEHYDE/POLYACRYLAMIDE CROSSLINKING INCOMPATIBILITY; FOR ACID STIMULATION OF WELLS NALCO/EXXON ENERGY CHEMICALS, L.P. (US) 2000-09-12 US disclosed
WO-1999040888-A1 COMPOSITIONS AND METHODS OF TREATING KERATIN-RELATED DISORDERS AND CONDITIONS BUCK CAROL J (US) 1999-08-19 WO disclosed
EP-0787228-A4 CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT COMMW SCIENT IND RES ORG (AU) 1998-09-02 EP disclosed
EP-0787228-A1 CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1997-08-06 EP disclosed
WO-1996012057-A1 CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1996-04-25 WO disclosed
EP-0608217-A1 SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1994-08-03 EP disclosed
EP-0608217-A4 SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION. RES CORP TECHNOLOGIES INC (US) 1993-12-06 EP disclosed
WO-1991016067-A1 SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1991-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12022829-B2 Water-dispersible fine particle ABCG2, FIBP, MMP1 PTGS1 1898/4885SLC7A11 591/4885ARG1 495/4885
US-20220030861-A1 WATER-DISPERSIBLE FINE PARTICLE ABCG2, FIBP, MMP1 PTGS1 1898/4885SLC7A11 591/4885ARG1 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.